Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Epigral Ltd Performance

Today's Low
1,281.95
arrowIcon
Today's High
1,318.20
52 Wk Low
862.05
arrowIcon
52 Wk High
1,400.00


Open

1289

Traded Value (Cr)

14.56 Cr

Prev. Close

1296.6

VWAP

1299.65

Volume

1,30,648

Face Value

10

Epigral Ltd Fundamentals

Market Cap
₹ 5,440 Cr
P/E Ratio (TTM)
27.85
P/B Ratio
4.82
Debt to Equity
0.86
ROE
19.80 %
EPS (TTM)
47.01
Dividend Yield
0.38%
Book Value
271.56

Click here to know more about Fundamentals

Epigral Ltd Financials

Epigral Ltd Financials

Epigral Ltd Shareholding Pattern

Held By Dec 2023 Sep 2023 Jun 2023 Mar 2023
Promoters 71.38 % 71.38 % 71.37 % 71.34 %
Retail 21.19 % 21.05 % 21.22 % 21.13 %
Others 6.20 % 6.38 % 6.20 % 6.29 %
FII 1.18 % 1.15 % 1.17 % 1.20 %
Mutual Funds 0.05 % 0.04 % 0.04 % 0.03 %

Promoters

71.38%

Retail

21.19%

Others

6.20%

FII

1.18%

Mutual Funds

0.05%

Promoters

71.38%

Retail

21.05%

Others

6.38%

FII

1.15%

Mutual Funds

0.04%

Promoters

71.37%

Retail

21.22%

Others

6.20%

FII

1.17%

Mutual Funds

0.04%

Promoters

71.34%

Retail

21.13%

Others

6.29%

FII

1.20%

Mutual Funds

0.03%

Resistance and Support

₹1,294.30

PIVOT

resistance-arrow
Resistance
First Resistance₹1,329.950
Second Resistance₹1,363.300
Third Resistance₹1,398.950
support-arrow
Support
First Resistance₹1,260.950
Second Resistance₹1,225.300
Third Resistance₹1,191.950
RSI74.470
MACD169.101
ADX24.147
CCI47.695

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day130,64858,64052.14
Week116,83879,76366.27
1 Month203,48370,95844.98
6 Months130,648130,648100.00

About Epigral Ltd

Meghmani Finechem Limited was incorporated in 2007 as a subsidiary of Meghmani organics ltd, under the provisions of Companies Act, 1956. The Company at present is primarily engaged in manufacturing and selling of Chlor Alkali & its Derivatives. The Company is also engaged in Trading of Agrochemical products. The Hon'ble National Company Law Tribunal ('NCLT') Ahmedabad Bench vide its order dated 3 May 2021 (the 'Order'), has approved the Scheme of Arrangement ('the Scheme') to demerge the Agrochemicals and Pigments Division of Meghmani Organics Limited ('MOL') along with its investment in Optionally Convertible Redeemable Preference Shares ('OCRPS') of Meghmani Finechem Limited ('MFL') and transferred to the Company as a going concern. The certified true copy of the Order issued by NCLT Ahmedabad Bench on 05th May, 2021 filed with The Ministry of Corporate Affairs (the 'MCA') Registrar of Companies ('ROC') Gujarat, Dadra, Nagar and Haveli on 10th May, 2021. The Scheme is effective from 10th May, 2021. By this Meghmani Finechem Limited was demerged from Meghmani Organics in FY 2020-21 to empower the Company grow its Chlor-Alkali business. The demerged Company is now being driven by the second generation of the promoter family that came on the Board of the Company in 2016. The Company's Chlor-Alkali business was commissioned in 2009, growing from an installed capacity of 1,88,000 TPA in 2015 to 3,15,000 TPA at the close of FY 2020-21. The Company is now among the leading players in India's chlor alkali industry. The Company grew its business following the commissioning of new plants (Caustic Soda, Hydrogen Peroxide and the 36 MW Captive Power Plant). The timely commissioning of the plants represented the faith of the management in the long-term potential of the sector and country. The Caustic Soda capacity was expanded by 1,27,000 TPA to 2,94,000 TPA and commissioned in June 2020. The Captive Power Plant capacity was increased by 36 MW to 96 MW, commissioned in June 2020. The Company commissioned a 60,000 TPA Hydrogen Peroxide plant in July 2020. The complement of these manufacturing capacities will broadbase the Company's manufacturing foundation, strengthen integration, moderate the cost structure and provide a platform for value-addition. The payback from these investments is likely to be recovered in 4-5 years, validating the Company's commitment to profitable growth. During the year under review 2020-21, the Company announced the implementation of a manufacturing facility for Epichlorohydrin (ECH) and Chlorinated Polyvinyl Chloride (CPVC) which are expected to add attractively to the Company's volumes and profitability across the future. The ECH project will be the first time that the product will be manufactured in India. The 50,000 TPA facility will be based on glycerin feedstock that is obtained from 100% renewable resources, addressing the need for cost-effectiveness and moderated carbon footprint. The project is likely to be commissioned during the first quarter of the next financial year. The CPVC Resin project of 30,000 TPA at a cost of H190 Cr is likely to be commissioned in the second quarter of FY 2022-23.

Managing Director

Maulik Jayantibhai Patel

Founded

2007

NSE Symbol

EPIGRAL

Epigral Ltd Management

NameDesignation
Maulik Jayantibhai PatelChairman & Managing Director
Kaushal Ashishbhai SoparkarManaging Director
Karana Rameshbhai PatelExecutive Director
Ankit Natwarlal PatelExecutive Director
Darshan Anandbhai PatelExecutive Director
Manubhai Khodidas PatelIndependent Director
NIRALI BHAVIN PARIKHIndependent Director
Sanjay K AsherIndependent Director
Kanubhai S PatelIndependent Director
Raju SwamyIndependent Director

Epigral Ltd News

Epigral to hold board meeting
On 22 April 2024
Epigral edges higher after commissioning 45,000 TPA CPVC resin capacity at Dahej
Epigral added 2.91% to Rs 1361.50 after the company announced the successful commissioning of an additional 45,000 tonnes per annum (TPA) capacity of CPVC (chlorinated polyvinyl chloride) resin plant at its Dahej facility in Gujarat.
Epigral commissions 45,000 TPA capacity of CPVC resin plant at Dahej
Epigral consolidated net profit declines 36.42% in the December 2023 quarter
Sales decline 12.33% to Rs 471.52 crore
Epigral to hold board meeting
On 24 January 2024
Epigral opens its first R&D centre at Ahmedabad, Gujarat
Epigral consolidated net profit declines 58.50% in the September 2023 quarter
Sales decline 13.93% to Rs 478.15 crore
Epigral to table results
On 6 November 2023
Epigral forays into CPVC compounding segments with 35,000 TPA capacity plant
Epigral has announced its expansion into chlorinated polyvinyl chloride (CPVC) compounds with the CPVC Compound manufacturing plant, which is is expected to get commissioned by Q4 FY24 at Dahej, Gujarat, and has a capacity of 35,000 TPA.
Epigral plans to add CPVC Compound capacity at Dahej
To commission 35,000 TPA capacity by Q4 FY24

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
PIDILITIND₹ 1,46,433 Cr
₹ 2,879.10
(-0.15 %)
84.42
SRF₹ 74,647 Cr
₹ 2,518.25
(-1.53 %)
49.17
LINDEINDIA₹ 58,986 Cr
₹ 6,916.85
(1.71 %)
140.03
FLUOROCHEM₹ 38,717 Cr
₹ 3,524.55
(-1.54 %)
56.36
DEEPAKNTR₹ 31,669 Cr
₹ 2,321.90
(1.00 %)
75.69

Epigral Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Epigral Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Epigral Ltd's share price is ₹1,295.05 as of April 16, 2024

Epigral Ltd's P/E ratio is 27.85 times as of April 16, 2024.

Epigral Ltd's most recent financial reports indicate a price-to-book ratio of 4.82, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Epigral Ltd's market is 5,440 Cr as on April 16, 2024.

The current financial records of Epigral Ltd show a 19.80% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Epigral Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Epigral Ltd's 52-week high and low as of April 16, 2024 are ₹1318.2 and ₹1281.95 respectively.

As of the Dec 2023 quarter, the promoter shareholding in Epigral Ltd stands at 71.38%. During the same period, Institutional Investors have shown a slight increase in their holdings, rising from 1.15% to 1.18%.